where does hims get their semaglutide Just Launched an Ozempic Dupe Hims & Hers makes deal

PMID: 44 MatwiejukMMysliwiecHJakubowicz-ZalewskaOChabowskiAFlisiakI

Tafech, B

doi: 10.1186/s12970-018-0238-7

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions

10.1055/s-0043-113455 Drug Res